14 Best Booming Stocks to Buy Right Now

Page 7 of 13

7. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)

Upside Potential: 60.14%

3M Returns: 23.73%

Number of Hedge Fund Holders: 31

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is among the 14 best booming stocks to buy right now. On January 12, Goldman Sachs analyst Richard Law upgraded the stock’s rating to Buy from Neutral, with a share price target of $67.

The adjustment followed promising results from a trial investigating the impact of atumelnant on congenital adrenal hyperplasia (CAH). The findings revealed a 67% reduction in A4 in Cohort 4, replicating the results in the first three cohorts. Moreover, about 7 in 8 participants maintained a reduction in androgen, despite cutting the glucocorticoid dosage to protocol levels.

In other news, Citizens analyst Jonathan Wolleben on January 8 slightly cut the firm’s price target on Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) to $105 from $108, while maintaining an earlier Outperform rating on the shares.

The analyst cited a survey by American endocrinologists that revealed ‘positive early experience’ with the company’s recently launched drug, Palsonify, to treat acromegaly. In a research note to investors, Law said that the survey supported the Q4 preliminary net product revenue of over $5 million that the company announced earlier in the week.

According to a report on TipRanks, Citizens expects Palsonify to continue exceeding expectations in 2026.

Overall, Wall Street analysts have a bullish outlook on the stock with a consensus Strong Buy rating with a one-year average share price target of $88.64, representing an upside potential of 60.14% as of the close on January 12.

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is a biopharmaceutical company that develops treatments for rare endocrine diseases and endocrine-related tumors.

Page 7 of 13